The company may no longer be operating, as it may be out of business. Find out why through their latest events.
Selectimmune Pharma Past Earnings Performance
Past criteria checks 0/6
Selectimmune Pharma's earnings have been declining at an average annual rate of -22.5%, while the Pharmaceuticals industry saw earnings growing at 13.7% annually.
How Selectimmune Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
NGM:SELECT B Revenue, expenses and earnings (SEK Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 23
0
-9
8
0
31 Dec 22
0
-9
9
0
30 Sep 22
0
-12
12
0
30 Jun 22
0
-14
14
0
31 Mar 22
0
-16
16
0
31 Dec 21
0
-15
15
0
30 Sep 21
0
-14
13
0
30 Jun 21
0
-13
12
0
31 Mar 21
0
-9
8
0
31 Dec 20
0
-9
9
0
30 Sep 20
0
-8
8
0
30 Jun 20
0
-8
8
0
31 Mar 20
0
-10
10
0
31 Dec 19
0
-9
9
0
30 Jun 19
0
-4
4
0
Quality Earnings: SELECT B is currently unprofitable.
Growing Profit Margin: SELECT B is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SELECT B is unprofitable, and losses have increased over the past 5 years at a rate of 22.5% per year.
Accelerating Growth: Unable to compare SELECT B's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SELECT B is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.8%).
Return on Equity
High ROE: SELECT B has a negative Return on Equity (-141.66%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2023/08/11 02:11
End of Day Share Price
2023/08/08 00:00
Earnings
2023/03/31
Annual Earnings
2022/06/30
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Selectimmune Pharma AB (publ) is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.